Business
Protara Therapeutics Announces Departure of Chief Financial Officer
NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the
About this update from Protara Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, June 21, 2022 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that Blaine Davis, Chief Financial Officer (CFO), has informed the Company that he will be leaving to pursue other opportunities. His last day at the Company will be July 15, 2022. “On behalf of our Board of Directors and the management team, I would like to thank Blaine for his leadership and build-out of our finance, commercial and IT functions and his many other contributions to our long-term growth and development,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “Blaine has built a talented and experienced team at Protara, and we believe we are in a strong financial and operational position as we continue to strive towards our goal of bringing transformative therapies to patients in areas of high unmet need.” “I would like to thank my colleagues at Protara for their partnership,” said Mr. Davis. “I’m confident that the team is well positioned to continue to execute on its mission to deliver meaningful oncology and rare disease therapeutics to patients.” Mr. Davis’ departure is not related to Protara’s operations, financial reporting or controls. As of March 31, 2022, the Company had cash, cash equivalents and investments of $119M expected to fund operations into mid-2024. About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are \"forward looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “...